944945-07-7 Usage
Uses
Used in Pharmaceutical Research:
BIX 01294 is used as a research compound for investigating the role of G9a histone methyltransferase in various diseases. Its application is crucial in understanding the epigenetic regulation of gene expression and the potential therapeutic implications in treating cancer, neurodegenerative disorders, and metabolic syndromes.
Used in Drug Development:
BIX 01294 serves as a lead compound in the development of novel therapeutics targeting G9a histone methyltransferase. Its ability to modulate gene expression and impact cellular processes makes it a promising candidate for the creation of new drugs to treat a range of diseases.
Used in Epigenetic Studies:
In the field of epigenetics, BIX 01294 is employed as a tool to study the effects of histone methylation on gene expression and cellular function. This helps researchers gain insights into the molecular mechanisms underlying various diseases and the potential for targeted epigenetic therapies.
Used in Cancer Research:
BIX 01294 is used as an inhibitor of G9a histone methyltransferase in cancer research, aiming to understand its role in tumor development and progression. By targeting this enzyme, researchers can explore the potential of BIX 01294 in disrupting cancer-related pathways and its effectiveness as an anticancer agent.
Used in Neurodegenerative Disorder Research:
In the context of neurodegenerative disorders, BIX 01294 is utilized to study the involvement of G9a histone methyltransferase in the pathology of these conditions. Its application aids in uncovering the epigenetic factors contributing to the development of such disorders and the potential for therapeutic intervention.
Used in Metabolic Syndrome Research:
BIX 01294 is employed in metabolic syndrome research to investigate the role of G9a histone methyltransferase in the regulation of metabolic processes. This helps researchers understand the epigenetic factors influencing metabolic syndrome and the potential for targeted treatments to manage or alleviate the condition.
Check Digit Verification of cas no
The CAS Registry Mumber 944945-07-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,4,4,9,4 and 5 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 944945-07:
(8*9)+(7*4)+(6*4)+(5*9)+(4*4)+(3*5)+(2*0)+(1*7)=207
207 % 10 = 7
So 944945-07-7 is a valid CAS Registry Number.
944945-07-7Relevant academic research and scientific papers
Design and synthesis of tricyclic sulfones as γ-secretase inhibitors with greatly reduced Notch toxicity
Xu, Ruo,Cole, David,Asberom, Ted,Bara, Tom,Bennett, Chad,Burnett, Duane A.,Clader, John,Domalski, Martin,Greenlee, William,Hyde, Lynn,Josien, Hubert,Li, Hongmei,McBriar, Mark,McKittrick, Brian,McPhail, Andrew T.,Pissarnitski, Dmitri,Qiang, Li,Rajagopalan, Murali,Sasikumar, Thavalakulamgar,Su, Jing,Tang, Haiqun,Wu, Wen-Lian,Zhang, Lili,Zhao, Zhiqiang
experimental part, p. 2591 - 2596 (2010/07/05)
A novel series of tricyclic γ-secretase inhibitors was designed and synthesized via a conformational analysis of literature compounds. The preliminary results have shown that compounds in this new series have much improved in vitro potency and in vivo pro
BENZENESULFONYL-CHROMANE, THIOCHROMANE, TETRAHYDRONAPHTHALENE AND RELATED GAMMA SECRETASE INHIBITORS
-
Page/Page column 466, (2009/03/07)
Disclosed are novel gamma secretase inhibitors of the formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, wherein L1, n, X, Ar, Y, Z, Q, and Q1 are as defined herein. Also disclosed are methods for inhibiti
BENZENESULFONYL-CHROMANE, THIOCHROMANE, TETRAHYDRONAPHTHALENE AND RELATED GAMMA SECRETASE INHIBITORS
-
Page/Page column 115; 120, (2010/11/28)
This invention discloses novel gamma secretase inhibitors of the formula: R2 and R3, or R2 and R4, or R3 and R4, together with the atoms to which they are bound, can form a fused cycloalkyl
